Argentina vs Panama: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Argentina
79.0%
in 2025
Panama
77.0%
in 2025
Argentina rank
121st
Panama rank
124th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Argentina
- Panama
How they compare
Argentina currently reports 79.0% against 77.0% in Panama, a difference of 2.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Panama ahead.
Argentina ranks 121st and Panama ranks 124th of 194 countries.
Panama has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Argentina | Panama | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 62.6% | 84.2% | 21.6% | Panama |
| 2020s | 77.0% | 80.7% | 3.7% | Panama |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Argentina or Panama?
- Argentina, at 79.0% against 77.0% in Panama as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Argentina and Panama?
- 2.0%, with Argentina ahead.
- How many years of comparable data are there for Argentina and Panama?
- 18 years are reported by both, from 2008 to 2025.
- How do Argentina and Panama rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Argentina ranks 121st and Panama ranks 124th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.